Lapierre Y D, Angus C, Awad A G, Saxena B M, Jones B, Williamson P, Vincent P, Carle R, Lavallee Y J, Manchanda R, Gauthier B, Wolf M A, Teehan M D, Denis J F, Malla A K, Oyewumi L K, Busse E, Labelle A, Claesson L, Grafford K
Department of Psychiatry, Royal Ottawa Hospital, Ontario, Canada.
Int Clin Psychopharmacol. 1999 Mar;14(2):101-12. doi: 10.1097/00004850-199903000-00007.
The primary objective of this study was to evaluate the efficacy, safety and tolerability of remoxipride (controlled release) versus haloperidol in patients with negative symptoms. The study comprised a multicentre, randomised, double-blind, parallel-group clinical trial. Two hundred and five patients were randomised to either remoxipride or haloperidol. Patients eligible for this study were aged 18-65 years, met the DSM-III-R diagnosis for chronic schizophrenia and the Positive and Negative Symptoms Scale (PANSS) criteria for predominant negative symptoms. There was a statistically significant reduction in the PANSS scores of at least 20% from baseline to last rating for 39 remoxipride (49.4%) and 45 haloperidol (47.6%) treated patients. There were no statistical differences found between the two treatment groups with respect to improvement of negative symptoms and adverse events. The PANSS data suggest that both remoxipride and haloperidol improve the cluster of negative symptoms concerned with social functioning. In addition, the design of the study provides a methodology that is appropriate to the study of primary negative symptoms in schizophrenia.
